These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Physicians, pharmaceutical representatives, and patients: who really benefits? Westfall JM J Fam Pract; 2000 Sep; 49(9):817-9. PubMed ID: 11032206 [No Abstract] [Full Text] [Related]
4. The regulatory morass: physicians' dealings with pharmaceutical manufacturers. Blehart B J Med Pract Manage; 2003; 19(3):164-5. PubMed ID: 14730825 [No Abstract] [Full Text] [Related]
5. Doctor, do you have a minute? The dilemma posed by physician interaction with the pharmaceutical industry. Quan SF J Clin Sleep Med; 2007 Jun; 3(4):345-6. PubMed ID: 17694720 [No Abstract] [Full Text] [Related]
6. Conflict of interest in the physician interface with the biomedical industry. Minnigan H; Chisholm CD Emerg Med Clin North Am; 2006 Aug; 24(3):671-85. PubMed ID: 16877136 [TBL] [Abstract][Full Text] [Related]
7. [Drug industry and physicians--once more]. Werkö L Lakartidningen; 1991 May; 88(22):2041-2. PubMed ID: 2051867 [No Abstract] [Full Text] [Related]
8. [Relations between physicians and the pharmaceutical industry]. Ruiz-Argüelles GJ Rev Invest Clin; 1997; 49(1):79-80. PubMed ID: 9229760 [No Abstract] [Full Text] [Related]
9. The economic wisdom of regulating pharmaceutical "freebies". Fisher SH Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416 [No Abstract] [Full Text] [Related]
10. Marketing pharmaceutical products to physicians. Sales reps influence physicians' impressions of the industry. Creyer EH; Hrsistodoulakis I Mark Health Serv; 1998; 18(2):34-8. PubMed ID: 10180333 [TBL] [Abstract][Full Text] [Related]
11. Interaction between physicians and the pharmaceutical industry. Arkinstall WW CMAJ; 1995 Aug; 153(4):398-9. PubMed ID: 7634216 [No Abstract] [Full Text] [Related]
13. A tangled love affair. Fox ER West J Med; 1989 Apr; 150(4):484. PubMed ID: 2735060 [No Abstract] [Full Text] [Related]
14. Physicians and the pharmaceutical industry. Squires BP CMAJ; 1993 Nov; 149(10):1391-2. PubMed ID: 8221422 [No Abstract] [Full Text] [Related]
15. A study of interactions between pharmaceutical representatives and ophthalmology trainees. Wang Y; Adelman RA Am J Ophthalmol; 2009 Oct; 148(4):619-622.e3. PubMed ID: 19570520 [TBL] [Abstract][Full Text] [Related]
16. Ethics, profit and patients: when pharmaceutical companies sponsor medical meetings. Barton L J Hosp Mark; 1993; 8(1):71-82. PubMed ID: 10135504 [TBL] [Abstract][Full Text] [Related]
17. Opinions of pharmacy, medicine, and pharmaceutical industry leaders about hypothetical therapeutic-interchange legislation. Segal R; Grines LL; Pathak DS Am J Hosp Pharm; 1988 Mar; 45(3):570-7. PubMed ID: 3369459 [TBL] [Abstract][Full Text] [Related]
18. What drug rep visits cost you. Lowes R Med Econ; 2007 Aug; 84(15):49-51. PubMed ID: 17853853 [No Abstract] [Full Text] [Related]
19. Interacting with the pharmaceutical industry. Greenwald M CMAJ; 1994 Sep; 151(6):731; author reply 732. PubMed ID: 8087745 [No Abstract] [Full Text] [Related]
20. The role of the medical doctor in the pharmaceutical industry. Fitzgerald JD Int Z Klin Pharmakol Ther Toxikol; 1968 Jul; 1(5):447-54. PubMed ID: 4882610 [No Abstract] [Full Text] [Related] [Next] [New Search]